Cargando…

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. The primary aim of this retrospective, multicenter study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Rohini, Pillai, Anjana, Marron, Thomas Urban, Fessas, Petros, Saeed, Anwaar, Jun, Tomi, Dharmapuri, Sirish, Szafron, David, Naqash, Abdul Rafeh, Gampa, Anuhya, Wang, Yinghong, Khan, Uqba, Muzaffar, Mahvish, Lee, Chieh‐Ju, Lee, Pei‐Chang, Bulumulle, Anushi, Paul, Sonal, Bettinger, Dominic, Hildebrand, Hannah, Yehia, Mohammed, Pressiani, Tiziana, Kaseb, Ahmed, Huang, Yi‐Hsiang, Ang, Celina, Kudo, Masatoshi, Nishida, Naoshi, Personeni, Nicola, Rimassa, Lorenza, Pinato, David James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234627/ https://www.ncbi.nlm.nih.gov/pubmed/35481940 http://dx.doi.org/10.1002/hep4.1927

Ejemplares similares

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
por: Pinato, David J., et al.
Publicado: (2020)

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
por: Muhammed, Ambreen, et al.
Publicado: (2021)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
por: Jun, Tomi, et al.
Publicado: (2021)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
por: Marinelli, Brett, et al.
Publicado: (2022)

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
por: D’Alessio, Antonio, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
por: Cammarota, Antonella, et al.
Publicado: (2022)

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
por: Personeni, Nicola, et al.
Publicado: (2020)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021)

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
por: Marie, Mona A., et al.
Publicado: (2022)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Bilateral orbital myeloid sarcoma preceding acute myeloid leukemia in an adult: a case report and review of the literature
por: Vera-Aguilera, Jesus, et al.
Publicado: (2016)

Progressive changes in platelet counts and Fib-4 scores precede the diagnosis of advanced fibrosis in NASH patients
por: Zijlstra, Michael K, et al.
Publicado: (2023)

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
por: Joerg, Vincent, et al.
Publicado: (2023)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

Immune-based therapies for hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2020)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
por: Santoro, A, et al.
Publicado: (2010)

The Mechanism of Enhanced Insulin Amyloid Fibril Formation by NaCl Is Better Explained by a Conformational Change Model
por: Muzaffar, Mahvish, et al.
Publicado: (2011)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study
por: Personeni, Nicola, et al.
Publicado: (2022)

Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients
por: Milana, Flavio, et al.
Publicado: (2022)

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
por: Choucair, Khalil, et al.
Publicado: (2023)

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review
por: Moole, Harsha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7o9hkb3dhfah41kimnmvah0cfo